These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 24602118)

  • 1. Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment.
    van Staa TP; Carr DF; O'Meara H; McCann G; Pirmohamed M
    Br J Clin Pharmacol; 2014 Sep; 78(3):649-59. PubMed ID: 24602118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care.
    García-Rodríguez LA; Massó-González EL; Wallander MA; Johansson S
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):943-52. PubMed ID: 18425988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of elevated creatine phosphokinase between daptomycin alone and concomitant daptomycin and statins: A systematic review and meta-analysis.
    Samura M; Takada K; Hirose N; Kurata T; Nagumo F; Koshioka S; Ishii J; Uchida M; Inoue J; Enoki Y; Taguchi K; Tanikawa K; Matsumoto K
    Br J Clin Pharmacol; 2022 May; 88(5):1985-1998. PubMed ID: 34902879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases.
    García-Rodríguez LA; González-Pérez A; Stang MR; Wallander MA; Johansson S
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):953-61. PubMed ID: 18425987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
    Meek C; Wierzbicki AS; Jewkes C; Twomey PJ; Crook MA; Jones A; Viljoen A
    Curr Med Res Opin; 2012 Mar; 28(3):371-8. PubMed ID: 22256801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of rosuvastatin.
    Shepherd J; Hunninghake DB; Stein EA; Kastelein JJ; Harris S; Pears J; Hutchinson HG
    Am J Cardiol; 2004 Oct; 94(7):882-8. PubMed ID: 15464670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosuvastatin (Crestor) and rhabdomyolysis.
    Wooltorton E
    CMAJ; 2004 Jul; 171(2):129. PubMed ID: 15262879
    [No Abstract]   [Full Text] [Related]  

  • 8. Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability.
    Golightly LK; Barber GR; Barron MA; Page RL
    Drug Metabol Drug Interact; 2013; 28(1):49-58. PubMed ID: 23314530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program.
    Shepherd J; Vidt DG; Miller E; Harris S; Blasetto J
    Cardiology; 2007; 107(4):433-43. PubMed ID: 17363845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosuvastatin and the statin wars--the way to peace.
    Meyboom RH; Edwards IR
    Lancet; 2004 Dec 4-10; 364(9450):1997-9. PubMed ID: 15582043
    [No Abstract]   [Full Text] [Related]  

  • 11. Incidence of skeletal muscle disorders after statins' treatment: consequences in clinical and EMG picture.
    Drobny M; Pullmann R; Odalos I; Skerenova M; Saniova B
    Neuro Endocrinol Lett; 2014; 35(2):123-8. PubMed ID: 24878976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients.
    Kasliwal R; Wilton LV; Cornelius V; Aurich-Barrera B; Shakir SA
    Drug Saf; 2007; 30(2):157-70. PubMed ID: 17253880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance.
    Davidson MH
    Expert Opin Drug Saf; 2004 Nov; 3(6):547-57. PubMed ID: 15500414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of incident diabetes among patients treated with statins: population based study.
    Carter AA; Gomes T; Camacho X; Juurlink DN; Shah BR; Mamdani MM
    BMJ; 2013 May; 346():f2610. PubMed ID: 23704171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study.
    Goettsch WG; Heintjes EM; Kastelein JJ; Rabelink TJ; Johansson S; Herings RM
    Pharmacoepidemiol Drug Saf; 2006 Jul; 15(7):435-43. PubMed ID: 16761304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
    Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. McArdle disease with rhabdomyolysis induced by rosuvastatin: case report.
    Lorenzoni PJ; Silvado CE; Scola RH; Luvizotto M; Werneck LC
    Arq Neuropsiquiatr; 2007 Sep; 65(3B):834-7. PubMed ID: 17952291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. By the way, doctor. I am 80 and am taking a 40-milligram Crestor pill every day. Recently I saw a Crestor ad that said blood tests should be done to monitor for possible side effects of liver or muscle injury. Can you tell me something about those tests?
    Komaroff AL
    Harv Health Lett; 2007 Mar; 32(5):8. PubMed ID: 17390496
    [No Abstract]   [Full Text] [Related]  

  • 19. Rosuvastatin: renal disorders and rhabdomyolysis.
    Prescrire Int; 2007 Apr; 16(88):68-9. PubMed ID: 17458050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosuvastatin induced rhabdomyolysis in a low risk patient: a case report and review of the literature.
    Khan FY; Ibrahim W
    Curr Clin Pharmacol; 2009 Jan; 4(1):1-3. PubMed ID: 19149497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.